Staying in the back seat to Keytruda, Bristol Myers reports another pivotal setback in urothelial cancer
Just a few weeks after Bristol Myers Squibb and Nektar put the kibosh to their combo study of Opdivo and bempeg for metastatic urothelial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
